"Challenges in Lowering Prescription Drug Prices: Trump's Executive Order and the Role of Big Pharma and PBMs"
Read "Challenges in Lowering Prescription Drug Prices: Trump's Executive Order and the Role of Big Pharma and PBMs" on WALY Radio
"Challenges in Lowering Prescription Drug Prices: Trump's Executive Order and the Role of Big Pharma and PBMs"
[!CDATA[President Donald Trump recently signed an executive order aimed at reducing prescription drug prices for Americans by aligning them with prices in other countries. The order targets the high prices paid in the U.S. for medications like Abilify and Zepbound. However, experts question the legality of the proposal, as it blames other countries for high prices rather than addressing corporate monopolies like Big Pharma and pharmacy benefit managers (PBMs) that drive up costs domestically. While Trump's order criticizes drug manufacturers, it fails to address the profiteering and price gouging by Big Pharma and PBMs. The order overlooks the role of PBMs, such as UnitedHealth Group, in inflating drug prices. American patients face exorbitant costs for prescriptions, with prices nearly three times higher than in other high-income countries. The rising costs have led to concerns about affordability and non-adherence to prescribed medications. Big Pharma contributes to the high drug prices by manipulating the patent system to block cheaper generic alternatives. Despite claiming that high prices fund research and development, reports show that excessive pricing benefits executives and shareholders more than innovation. Lowering drug costs for Americans requires holding Big Pharma and PBMs accountable for their role in the pricing crisis. Trump's executive order proposes tying U.S. drug prices to those in other countries to lower costs for American patients. However, the order's effectiveness is uncertain, as drug manufacturers could potentially raise prices in other countries to offset losses. Legal challenges are expected to arise, similar to a previous executive order that was blocked by a federal judge. The markets have reacted with drug manufacturer shares surging following the announcement, indicating skepticism about the order's impact on drug pricing.]]